Valuation: Protalix BioTherapeutics, Inc.

Market Cap 22Cr 19Cr 18Cr 17Cr 31Cr 2.1TCr 31Cr 217.35Cr 84Cr 1.07TCr 82Cr 81Cr 3.45TCr P/E 2026 *
11.3x
P/E 2027 * 54.4x
Enterprise Value 22Cr 19Cr 18Cr 17Cr 31Cr 2.1TCr 31Cr 217.35Cr 84Cr 1.07TCr 82Cr 81Cr 3.45TCr EV / Sales 2026 *
2.67x
EV / Sales 2027 * 3.3x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week+1.12%
Current month+5.84%
1 month+13.33%
3 months+22.52%
6 months+25.93%
Current year+51.11%
1 week 2.69
Extreme 2.69
2.85
1 month 2.48
Extreme 2.48
2.85
Current year 1.72
Extreme 1.72
3.19
1 year 1.6
Extreme 1.6
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Free

Director

25,500 0.0316%
03/09/26 Free

Chairman

25,500 0.0316%
03/09/26 Free

Chief Executive Officer

4,80,000 0.5957%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%+1.12%+33.33%+63.86% 22Cr
+0.13%+2.65%+65.61%+114.28% 1,05500Cr
+0.20%+0.46%+52.60%+69.24% 65TCr
-0.29%+0.14%+20.96%+70.93% 47TCr
-0.85%+0.98%+41.29%+44.38% 35TCr
+0.71%+4.08%+22.24%+29.51% 27TCr
+1.23%+0.42%+14.57%+12.13% 26TCr
+2.11%+7.51%+52.89%+55.37% 22TCr
+0.83%+0.55%+35.99%+101.70% 19TCr
0.00%-10.14%-29.94%-60.30% 17TCr
Average +0.21%+0.85%+30.96%+50.11% 36.39TCr
Weighted average by Cap. +0.02%+1.32%+41.53%+67.83%

Financials

2026 *2027 *
Net sales 8.22Cr 7.21Cr 6.81Cr 6.21Cr 12Cr 787.44Cr 12Cr 81Cr 32Cr 402.29Cr 31Cr 30Cr 1.29TCr 6.65Cr 5.83Cr 5.51Cr 5.02Cr 9.4Cr 637.17Cr 9.47Cr 66Cr 26Cr 325.52Cr 25Cr 24Cr 1.05TCr
Net income 1.96Cr 1.72Cr 1.63Cr 1.48Cr 2.78Cr 188.16Cr 2.8Cr 19Cr 7.54Cr 96Cr 7.37Cr 7.21Cr 308.94Cr 37.94L 33.29L 31.44L 28.65L 53.64L 36Cr 54.02L 3.76Cr 1.46Cr 19Cr 1.42Cr 1.39Cr 60Cr
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
25/26/25 $2.720 -1.09% 3,86,025
24/26/24 $2.750 -1.79% 3,02,700
23/26/23 $2.800 -1.41% 5,86,410
22/26/22 $2.840 +3.27% 8,54,901
21/26/21 $2.750 +2.23% 4,71,379
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.720USD
Average target price
11.00USD
Spread / Average Target
+304.41%

Quarterly revenue - Rate of surprise